This study was conducted to analyze the feasibility of adjuvant capecitabine therapy using a tailoreddose escalation strategy in elderly patients with colon cancer (CC).
introduction
Approximately 50% of patients diagnosed with colorectal cancer (CRC) are ‡70 years of age [1] . However, elderly patients with colon cancer (CC) are known to be treated with chemotherapy less frequently than young patients [2] . Concerns about the impact of chemotherapy on toxicity or the patient's quality of life (QoL) are major reasons for undertreatment in elderly patients. However, there is reliable evidence supporting the use of adjuvant chemotherapy in elderly CC patients [3, 4] . Despite the suggested benefits of adjuvant therapy in elderly CC patients, the report from the ACCENT database showed that only 17.1% of patients enrolled in recent phase III trials, which evaluated adjuvant chemotherapy, were ‡70 years [5] . Because only fit elderly patients with a good performance status (PS) are enrolled in clinical trials, the data on adjuvant chemotherapy in elderly CC patients from the general population are limited. Therefore, clinicians have difficulty in deciding how to treat elderly patients in clinical practice.
In the X-ACT trial, capecitabine, an oral fluoropyrimidine, was shown to be equivalent to i.v. bolus 5-fluorouracil (5-FU) plus leucovorin (LV) treatment in patients with stage III CC in terms of disease-free survival (DFS) and overall survival (OS). Capecitabine was associated with fewer adverse effects than bolus 5-FU plus LV. Moreover, capecitabine showed no safety differences between patients <65 and ‡65 years of age [6, 7] . Considering the efficacy and tolerability, capecitabine is thought to be ideal for use in elderly CC patients receiving adjuvant therapy. However, there are very little data regarding the safety, tolerability, or efficacy of adjuvant capecitabine therapy in CC patients ‡70 years of age. Moreover, the standard dose of capecitabine (2500 versus 2000 mg/m 2 /day) has not been determined in the adjuvant setting for elderly CC patients, although a reduced dosage (2000 mg/m 2 /day, days 1-14 every 3 weeks) is commonly used in elderly patients with various solid tumors for reducing toxicity and increasing compliance [8] [9] [10] . However, monotonous fixed dose reduction to 2000 mg/m 2 /day in all elderly patients without considering the tolerability of individual patients may compromise the efficacy of treatment.
The goal of this prospective study was to analyze the feasibility of capecitabine therapy using a tailored-dose strategy in terms of dose intensity (DI), tolerability, and efficacy in elderly CC patients. In addition, changes in the QoL during capecitabine therapy and clinical parameters predicting reduced administration of capecitabine dosage were also analyzed.
methods patients
Consecutive patients ‡70 years of age with colonic adenocarcinoma were enrolled. Patients were required to be fully recovered from curative surgery (complete resection) for CC. Adjuvant capecitabine therapy was initiated within 8 weeks from the date of surgery. Patients with high-risk stage II (poorly differentiated adenocarcinoma, lymphovascular invasion, bowel obstruction or perforation, T4 stage, or number of resected lymph nodes <12) or stage III CC were included. Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) PS of zero to two, adequate hematologic [absolute neutrophil count (ANC) ‡ 1.5 · 10 9 /l and platelet count ‡ 100 · 10 9
/l], hepatic [serum bilirubin £ 1.5 · upper normal limit (UNL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) £ 2.5 · UNL], and renal function [estimated creatinine clearance (Ccr) using Cockcroft-Gault formula ‡30 ml/min]. Patients with serious underlying medical conditions that would impair the ability to receive chemotherapy were excluded. This study was approved by the institutional review board and the first patient was enrolled in March 2005.
study design and treatment
Capecitabine was administered orally twice daily on days 1-14 every 3 weeks. Toxic effects were evaluated according to the National Cancer Institute-Common Toxicity Criteria for Adverse Events (version 3.0). Subsequent chemotherapy cycles were initiated after hematologic toxic effects were recovered, as follows: ANC ‡ 1.5 · 10 9 /l, platelet count ‡ 100 · 10 9 /l, and all nonhematologic toxic effects recovered to £grade 1. A total of eight cycles of capecitabine was planned. The dose level +1 (DL+1), 0 (DL0), and 21 (DL21) of capecitabine were defined as 1250, 1000, and 750 mg/m 2 twice daily, respectively. In all patients, the starting dose was DL0, and on the first day of the second cycle of capecitabine, the DL was determined according to the grade of toxic effects during the first cycle. If maximal toxicity grades were £1 during the first cycle, dose escalation to DL+1 was attempted in the second cycle. If the maximal toxicity grade was 2, DL was maintained (DL0) in the second cycle. If the maximal toxicity grade was 3 or 4, the dose of capecitabine was reduced to DL21 or permanently discontinued (Figure 1 ). After the second cycle, dose modification was carried out as shown in Table 1 . If severe toxicity developed again in patients at DL21, capecitabine treatment was permanently discontinued.
evaluation during pretreatment, chemotherapy, and follow-up periods
Before the initiation of capecitabine therapy, a physical examination, PS, and laboratory tests (complete blood count and serum chemistry) were assessed. During chemotherapy, these clinical parameters were evaluated every 3 weeks. The Charlson-Age comorbidity index (CACI) was calculated before capecitabine treatment [11] . After the fourth and eighth cycles of chemotherapy, disease status was assessed based on the carcinoembryonic antigen (CEA) level, chest radiography, and abdominopelvic computed tomography (CT) or ultrasonography. After the completion of chemotherapy, patients were evaluated every 3 months until 2 years, then every 6 months until 5 years after surgery. A physical examination, CEA measurement, and abdominal imaging (ultrasonography or CT) were carried out at every visit and the chest CT was carried out annually.
measurement of QoL
In December 2005, the study protocol was modified and QoL data were additionally collected. At baseline, 3 and 6 months during adjuvant chemotherapy, and 9-12 months after enrollment (3$6 months after the completion of therapy), patients filled out the Korean version of the European Organisation for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30) [12] . The EORTC QLQ-C30 consists of five functional scales, one global scale, and nine symptom scales. Raw scores of the global scale (QL) and five functional scales, including physical functioning, role functioning (RF), emotional functioning, cognitive functioning (CF), and social functioning (SF), were linearly transformed to a 0-100 scale. A higher score represents a better level of functioning. Nine symptom scales related to cancer were fatigue (FA), nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss (AP), constipation (CO), diarrhea (DI), and financial difficulties (FI). These scores were also transformed to a 0-100 scale. A high score represents more severe symptoms. Changes in the transformed score were analyzed by anchor-based interpretation. Mild, moderate, and severe changes were defined as a change in the score by 5-10, 10-20, and >20, respectively [13] . We defined moderate or severe changes as significant changes.
statistical analysis
The DI was calculated as the dose of capecitabine administered per cycle during the entire course of treatment. The relative dose intensity (RDI) was calculated according to the method of Hryniuk [14] . To analyze the clinical parameters predicting the reduced dosage administration of capecitabine, univariate (v 2 test) and multivariate analyses (logistic regression test) were carried out. In the logistic regression test, a stepwise forward regression model in which each variable with a P value < 0.10 in the univariate analysis was entered in the model. DFS was measured from the date of surgery to the date of recurrence or death, regardless of the causes and whichever occurred first. Recurrence-free survival (RFS) was measured from the date of surgery to the date of tumor recurrence or death with evidence of recurrence; patients who died of other comorbidities without tumor recurrence were censored on the date of death. OS was measured from the date of surgery to the date of death from any cause. Survival analysis was carried out using the Kaplan-Meier method. Statistical analyses were carried out with SPSS software (SPSS, Inc., Chicago, IL). All P values were two-sided, with a P < 0.05 indicating statistical significance. . Approximately one-third of the patients had an ECOG PS of two and the CACI was ‡8 in 24.4% of the patients. The patient characteristics are shown in Table 2 .
treatment and dose modification
Five hundred and eighty-two cycles of capecitabine with a median of 8 cycles (range, 1-8) were administered. Of 82 patients, dose escalation to DL+1 after completion of the first cycle was possible in 56 patients (68.3%). Sixty-seven patients (81.7%) completed eight cycles. The remaining 15 patients discontinued capecitabine for the following reasons: relapse, toxicity, declined treatment, or aggravation of comorbidities. Of 67 patients who completed eight cycles, DL+1 and DL0 were maintained in 24 patients each, and 19 patients had a dose reduction to DL21 (Figure 2 ). The RDI was calculated considering DL+1 (2500 mg/m 2 /day on days 1-14 every 3 weeks; 1667 mg/m 2 /day) as 100%. The mean RDI for all of the enrolled patients through the entire course of capecitabine therapy was 81.3% (range, 60.0%-100%). Forty-one patients (50.0%) completed eight cycles of treatment with an RDI maintenance ‡80% (1333 mg/m 2 /day). However, 41 patients (50.0%) could not complete eight cycles or completed eight cycles of therapy with an RDI < 80%. The change in DIs through the entire course of capecitabine therapy is demonstrated in Figure 3 ; the DIs were continuously decreased after the second cycle, but the final DI through the entire course of therapy was above the DI of DL0 (2000 mg/m 2 /day on days 1-14 every 3 weeks; 1333 mg/m 2 /day).
toxic effects
Hematologic and nonhematologic adverse events are shown in Table 3 . There were no treatment-related deaths. Grade 3/4 hematologic toxicity was <1.0%. The most common nonhematologic toxicity was hand-foot syndrome (HFS); 31 (37.8%) and 21 patients (25.6%) had grade 1/2 and grade 3 HFS, respectively. Fifteen patients did not complete eight cycles of capecitabine because of relapse (N = 2), toxicity (N = 6), declined treatment (N = 4), and aggravation of other underlying diseases (N = 3).
survival outcomes
As of December 2010, the median duration of follow-up of all patients was 45.0 months. Six patients died of comorbidities without evidence of CC recurrence. The 3-year DFS rates of patients with stage II (high risk) and III CC were 75.2% and 56.2%, respectively ( Figure 4A ). The 3-year RFS 
clinical parameters predicting the RDI of capecitabine
Clinical factors predicting the completion of eight cycles of capecitabine therapy with an RDI maintenance ‡80% were analyzed. Because 2 patients who developed tumor recurrence during chemotherapy were excluded, 80 patients were included in the following analyses. Based on univariate analysis, age < 75 years, CACI £ 7, and Ccr ‡ 50 ml/min were associated with the completion of eight cycles with an RDI ‡ 80% (P values < 0.05; Table 4 ); female gender showed a trend for completion of chemotherapy with an RDI ‡ 80% (P = 0.054). When these four clinical parameters (age, CACI, Ccr, and gender) with P values < 0.1 in univariate analyses were included in multivariate analysis, only a Ccr ‡ 50 ml/min [relative risk (RR), 0.25; 95% confidence interval (CI) 0.08-0.76; P = 0.015] and a CACI £ 7 (RR, 0.32; 95% CI 0.10-0.98; P = 0.046) were independently predictive of the completion of eight cycles with an RDI ‡ 80% ( Table 5) .
change of QoL scores during capecitabine therapy
Fifty-seven patients replied to the QLQ-C30 questionnaire. Of the 57 patients, 48 completed the questionnaire four times (baseline and 3, 6, and 9-12 months). Nine patients did not complete the questionnaires at all four times. Specifically, two patients only replied to the baseline questionnaire because the toxic effects of capecitabine interrupted chemotherapy permanently before the second questionnaire; four patients answered the first two questionnaires (baseline and 3 months) because chemotherapy was discontinued by toxicity (N = 2) and cancer recurrence (N = 2) before the completion of eight cycles of capecitabine; three patients completed three questionnaires (baseline and 3 and 6 months) because the fourth questionnaire could not be completed due to cancer recurrence (N = 1) or loss to follow-up (N = 2). The average scales for the global, functional, and symptom scales at the time of initiating chemotherapy are summarized in Figure 5 . The QL had the worst score, whereas other functional scales were preserved (>70). The cancer-related general symptoms, except for FA and AP, were not significant in most patients. During chemotherapy, no significant worsening of functional and global QoL occurred; a slight deterioration in functional scales observed at 3 months recovered with the passage of time. A significant improvement in the RF was observed after completion of chemotherapy ( Figure 6A ). Among the nine cancer-related symptoms, no symptoms were significantly exacerbated during therapy. FA and AP improved significantly after chemotherapy ( Figure 6B ).
discussion
Although capecitabine is commonly used in CC, the adequate dose of adjuvant capecitabine therapy in elderly patients ( ‡70 years) remains a matter of debate. In the X-ACT study [6, 7] , only CC patients £75 years of age were enrolled and capecitabine was used with a dose of 2500 mg/m 2 /day (days 1-14 every 3 weeks) in all patients without consideration of age; capecitabine showed similar safety profiles between patients <65 and ‡65 years of age. In the Oncopaz Cooperative Group Study [15] , elderly patients ( ‡70 years) with metastatic CRC were treated with capecitabine; the dose was 2500 mg/m 2 /day and patients with a Ccr of 30-49 ml/min received a dose of 1900 mg/m 2 /day (days 1-14 every 3 weeks). Bajetta et al. [8] treated patients ( ‡65 years) with metastatic breast cancer with two different doses of capecitabine (2000 versus 2500 mg/m 2 /day; days 1-14 every 3 weeks) and suggested that 2000 mg/m 2 /day was optimal for elderly patients. As capecitabine is known to be generally well tolerated with doses £2000 mg/m 2 /day (days 1-14 every 3 weeks), this dose is commonly used in elderly patients with solid tumors. However, elderly patients are very heterogeneous, thus a monotonous fixed dose reduction to 2000 mg/m 2 /day in all patients without considering the tolerability of individual patients may compromise the efficacy of adjuvant treatment. Moreover, if patients are able to tolerate a starting dose of 2000 mg/m 2 /day without signs of adverse events, increasing the capecitabine dose by 20% is recommended by many experts [10] . Based on these collective findings, a tailored-dose escalation strategy was used in the current study. To our knowledge, this is the first report involving a tailored-dose approach and QoL changes during adjuvant capecitabine therapy in elderly CC patients.
In the current study, all enrolled patients were ‡70 years of age and 50.0% of patients were ‡75 years old. Elderly patients original articles Annals of Oncology were consecutively enrolled in the clinical practice setting, thus approximately one-third of patients had an ECOG PS of two. The completion rate of the eight planned cycles was 81.7%, which was similar to the X-ACT study (83%) that included patients aged 18-75 years. With a tailored-dose escalation strategy, 24 patients (29.3%) completed eight cycles with a DL+1 and 41 patients (50.0%) completed eight cycles with an RDI maintenance ‡80%. The mean RDI during the entire course of therapy was 81.3%; it would never have been possible to maintain an RDI ‡ 80% if a fixed dose reduction strategy (2000 mg/m 2 /day) had been used during the entire course of chemotherapy cycles. In addition, the toxicity profiles were favorable (Table 3) ; the most common severe toxicity was HFS (25.6%). The toxicity profiles in our study were similar to the X-ACT study [6, 7] . The continuous decrease in DIs after the second cycle ( Figure 3 ) was primarily caused by severe HFS. With respect to QoL, although mild deterioration in some functioning scales (SF and CF) was observed at 3 months, the deterioration was not significant and recovered promptly; there was no exacerbation of cancer-related symptoms. Some scales (RF, FA, and AP) were significantly improved after completion of therapy ( Figure 6 ). Our data showed that compromised QoL after surgery in elderly CC patients was not worsened by adjuvant capecitabine therapy and improved after the completion of chemotherapy. Considering all of the favorable effects on RDI maintenance, the safety profiles, and QoL, our study showed that a tailored-dose escalation strategy of adjuvant capecitabine therapy in elderly patients is feasible. Additionally, the 3-year DFS, the 3-year RFS, and 5-year OS rates of elderly patients with stage III CC in the current study were 56.2%, 60.4%, and 70.1%, respectively ( Figure 4) ; these survival outcomes were in a similar range to the patients included in the X-ACT study [6] .
We analyzed the clinical parameters predicting reduced administration of capecitabine. Based on multivariate analysis, a CACI £ 7 and a Ccr ‡ 50.0 ml/min were associated with an RDI ‡ 80%. Capecitabine clearance is associated with renal function and decreased renal clearance is frequently observed in elderly patients [16] . Cassidy et al. [17] showed that the safety profile of capecitabine in patients with moderate renal impairment was different from that which occurs in patients with normal renal function. In our study, dose escalation in patients with a Ccr of 30-49 was attempted in the second cycle in the same manner as patients with a Ccr ‡ 50. We hypothesized that dose escalation might be tolerable if a capecitabine dose of 2000 mg/m 2 /day showed no or mild toxicity in the first cycle. However, only 30.4% of patients (6 of 22) with a Ccr < 50 achieved an RDI ‡ 80%. Our result confirms that Ccr is an important factor for dosage modification of capecitabine in elderly patients and dose escalation strategy is not appropriate in patients with a Ccr < 50. In addition, comorbidity was also an independent predictor of reduced administration of capecitabine; a CACI ‡ 8 was independently related to reduced administration of capecitabine. CACI is a simple index for the assessment of comorbidity [18] . In previous studies, this index was also reported to a prognostic factor for poor survival in elderly CRC patients [19, 20] . However, chronological age was not a significant predictor of reduced administration of capecitabine in the current study (Table 5) . Our study has some limitations. First, this study was carried out at a single institution, including a limited number of patients. Therefore, the observation from the current study cannot draw a definitive conclusion on the usefulness of tailored-dose strategy. However, we believe that our data strongly suggest the feasibility of a tailored-dose strategy in elderly CC patients receiving adjuvant capecitabine therapy considering the administered RDI, toxic effects, and QoL during chemotherapy. Second, some may criticize that patients included in our study had not received an oxaliplatin plus 5-FU regimen, which is now considered standard regimen as adjuvant chemotherapy for stage III patients [21] . However, as there is no definite evidence that adding oxaliplatin to 5-FU has superior efficacy to 5-FU alone in elderly CC patients in the adjuvant setting [5] , it is our opinion that patients enrolled in our study were not treated inadequately.
In conclusion, by using a tailored-dose escalation strategy, unnecessary dose reduction could be avoided without an increment of toxic effects in elderly CC patients receiving adjuvant capecitabine chemotherapy. The QoL was not compromised during treatment. Decreased renal function and an increased number of comorbidities were independent predictive factors for reduced administration of the capecitabine dose.
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